# Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

> **NCT06595498** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 130 (actual)

## Conditions studied

- Carcinoma, Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DIAGNOSTIC_TEST:** Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)
- **DIAGNOSTIC_TEST:** cobas® EGFR Mutation Test v2 (Roche)

## Key facts

- **NCT ID:** NCT06595498
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-06-30
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595498, "Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06595498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*